Matthew Montierth
@mattmontierth.bsky.social
PHD Candidate @ Baylor College of Medicine & MD Anderson Cancer Center | Computational Biology
As I gear up for my thesis defense next month, I'm thrilled to share the research that's been at the heart of my graduate work - now live on bioRxiv!
Current immunotherapy patient selection relies heavily on TMB (tumor mutational burden), but this criteria excludes about 85% of cancer patients.
Current immunotherapy patient selection relies heavily on TMB (tumor mutational burden), but this criteria excludes about 85% of cancer patients.
www.biorxiv.org
June 17, 2025 at 7:34 PM
As I gear up for my thesis defense next month, I'm thrilled to share the research that's been at the heart of my graduate work - now live on bioRxiv!
Current immunotherapy patient selection relies heavily on TMB (tumor mutational burden), but this criteria excludes about 85% of cancer patients.
Current immunotherapy patient selection relies heavily on TMB (tumor mutational burden), but this criteria excludes about 85% of cancer patients.